Methylene Blue vs P21
A side-by-side research comparison of Methylene Blue and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Methylene Blue | P21 |
|---|---|---|
| Full name | Methylene Blue (Methylthioninium Chloride) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | FDA-approved (off-label use) | Research compound |
| Mechanism | Acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing complex I-III blockades. Inhibits monoamine oxidase, tau aggregation, and provides antioxidant protection through auto-oxidation cycling. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 319.85 Da | ~450 Da |
| Half-life | 5-6.5 hours | 4-6 hours |
| Bioavailability | ~72% oral | Moderate (crosses BBB) |
| Typical dose | 0.5-2 mg/kg | 50-100 mcg/kg |
| Frequency | Daily or cycled | Daily |
| Route | Oral solution or sublingual | Intranasal or Subcutaneous |
Methylene Blue reported benefits
- Mitochondrial energy boost
- Cognitive enhancement
- Neuroprotection
- Anti-aging at cellular level
- Mood improvement
- Memory support
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.